Page 15 - Dr Reddy's Laboratories
Dr Reddy's recalls 50,000 bottles of Ondansetron tabs in US
USFDA says it's a class II recall, initiated when a drug may cause temporary or reversible adverse health conditions
 "Dr Reddy's recalls 50,000 bottles of Ondansetron tabs in US")
Dr Reddy's profit down 85%
The company saw surge in selling, general and administrative expense surge 7% year-on-year
Dr Reddy's Laboratories announces share buyback offer
The company proposes to spend Rs 1,569.41 crore to buy shares at a maximum price of Rs 3,500 per share
 "Dr Reddy's Laboratories announces share buyback offer")
Dr Reddy's, Japan's Eisai ink licensing pact for anti-cancer agent
Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr Reddy's holds the option for rights to develop and market the agent in India
 "Dr Reddy's, Japan's Eisai ink licensing pact for anti-cancer agent")
Dr Reddy's, TR-Pharm ink pact for biosimilar drugs in Turkey
Biosimilar products will be registered and commercialised by T-Pharm
 "Dr Reddy's, TR-Pharm ink pact for biosimilar drugs in Turkey")
Changes in excise rate rebate claim procedure will impact exporters: Dr Reddy's
Dr Reddy's and other large Indian pharmaceutical companies earn two-thirds of their revenues from exports, said the company's CFO
Dr Reddy's Lab extends rally after board nod for share buyback
The stock rallied 6.5% to Rs 3,154, extending its previous day's 3.6% gain on the National Stock Exchange.
 "Dr Reddy's Lab extends rally after board nod for share buyback")